NATURAL KILLER CELLS IN MUTANT CALRETICULIN-DRIVEN MYELOPROLIFERATIVE NEOPLASMS

EHA Library, Theresa Harm, 421580

SINGLE-CELL RNA SEQUENCING REVEALS THE MOLECULAR AND CELLULAR HETEROGENEITY OF MAST CELLS IN SYSTEMIC MASTOCYTOSIS

EHA Library, Ken-Hong Lim, 421581

IMMUNE PROFILING OF PERIPHERAL BLOOD LEUKOCYTE SUBSETS IN INDOLENT SYSTEMIC MASTOCYTOSIS

EHA Library, Cecilia Karlström, 421582

PROTEOMIC AND FUNCTIONAL ANALYSIS OF PLATELETS FROM ESSENTIAL THROMBOCYTHEMIA PATIENTS

EHA Library, Petros Papadopoulos, 421583

COMPARISON OF THE ENZYMATIC AND CELLULAR PROFILES OF CLINICAL JAK2 INHIBITORS FOR THE TREATMENT OF MYELOFIBROSIS

EHA Library, Ricardo Macarron, 421584

ANALYSIS OF MONOCYTE SUBPOPULATIONS BY FLOW CYTOMETRY IN THE DIFFERENTIAL DIAGNOSIS OF CLONAL VERSUS REACTIVE MONOCYTOSIS IN BLOOD. EXPERIENCE IN A TERTIARY HOSPITAL.

EHA Library, Jose-Maria Raya, 421585

ESSENTIAL THROMBOCYTHEMIA AND POLYCYTHEMIA VERA SHOW DIFFERENT JAK2V617F CLONAL EXPANSION BETWEEN ERYTHROID AND PLATELET LINEAGES

EHA Library, Olivier Mansier, 421587

DECIPHERING THE SPLEEN MICROENVIRONMENT IN MYELOFIBROSIS WITH SPATIAL TRANSCRIPTOMIC

EHA Library, Edoardo Peroni, 421588

THA DYNAMICS OF STROMAL CELLS IN MYELOPROLIFERATIVE NEOPLASMS DURING THE MYELOFIBROSIS.

EHA Library, Keiki Nagaharu, 421589

PROTEOMIC ANALYSIS OF SERUM OF PATIENTS WITH SYSTEMIC MASTOCYTOSIS

EHA Library, Christos Fokoloros, 421590

THE JAK2 46/1 HAPLOTYPE INFLUENCES PD-L1 EXPRESSION

EHA Library, Gonzalo Carreno Gomez-Tarragona, 421592

PREDICTING CALR MUTATIONS IN MPN USING ROUTINE HEMATOXYLIN AND EOSIN (H&E)-STAINED BONE MARROW BIOPSIES

EHA Library, Saad Bashir, 421593

INTRACELLULAR FUMARATE ACCUMULATION IN MYELOFIBROSYS MESENCHYMAL STROMAL CELLS TRIGGERS CELL SENESCENCE AND FIBROSIS ONSET.

EHA Library, Sebastiano Giallongo, 421594

EVALUATION OF IL-3 RECEPTOR ALPHA CHAIN AS POTENTIAL TARGET IN ADVANCED SYSTEMIC MASTOCYTOSIS

EHA Library, Narges Aghaallaei, 421595

CLONAL EVOLUTION IN SECUNDARY ACUTE MYELOID LEUKEMIA ARISING FROM MYELOPROLIFERATIVE NEOPLASMS

EHA Library, Sandra Martin, 421596

ALLELE POLYMORPHISM OF PLASMA HEMOSTATIC FACTORS GENES IN PRIMARY MYELOFIBROSIS

EHA Library, Natalia Korsakova, 421597

CLINICAL-PATHOLOGICAL CHARACTERIZATION OF MYELOPROLIFERATIVE AND MYELODEPLETIVE PHENOTYPES OF PRIMARY AND SECONDARY MYELOFIBROSIS

EHA Library, Simone Zoletto, 421598

UPREGULATION OF THE S100A8/S100A9 GENES LEADS TO RESISTANCE TO RUXOLITINIB IN PATIENTS WITH MYELOFIBROSIS AND MAY BE A DRIVING FACTOR IN BONE MARROW FIBROSIS.

EHA Library, Jian Huang, 421599

MUTANT MYELOID GENE CATEGORY MAY PREDICT POOR RESPONSE TO JAK INHIBITORS IN PATIENTS WITH MYELOFIBROSIS

EHA Library, Valentina Boldrini, 421600

USEFULNESS OF THE OPTICAL METHOD FOR PLATELET COUNT IN PATIENTS WITH MYELOFIBROSIS AND INFLUENCE OF THROMBOCYTOPENIA IN THERAPEUTIC MANAGEMENT

EHA Library, Vitor Botafogo, 421601

SORAFENIB TREATMENT IN A CASE OF  CLONAL EOSINOPHILIA WITH A TRIP11:FLT3 FUSION: ACHIEVING MOLECULAR TARGETS TO IMPROVE PROGNOSIS IN RARE DISEASES.

EHA Library, Isabel Montero, 421602

MYELOPROLIFERATIVE NEOPLASMS EMERGENCE AND DEVELOPMENT BASED ON REAL LIFE INCIDENCE AND MATHEMATICAL MODELING

EHA Library, Stephane Giraudier, 421603

HIGH PLATELET COUNT AND HIGH PLATELET-TO-LEUCOCYTES RATIO MAY DIFFERENTIATE POLYCYTHEMIAVERA FROM SECONDARY POLYCYTHEMIA

EHA Library, Manel Kasdallah, 421604

HYPOXIA-INDUCIBLE FACTOR-1 IS PATHOLOGICALLY ACTIVATED BY PIM1 PHOSPHORYLATION IN JAK2V617F MYELOPROLIFERATIVE NEOPLASMS, INITIATING A NON-CANONICAL HYPOXIC RESPONSE THAT DRIVES DISEASE PROGRESSION.

EHA Library, Katherine Bridge, 421605

ERYTHROCYTOSIS AS AN UNUSUAL SYMPTOM IN A COMPOUND HETEROZYGOTE IN THE ABCC6 GENE

EHA Library, Dagmar Pospíŝilová, 421606

THROMBOSES IN POLYCYTHEMIA VERA AND ESSENTIAL THROMBOCYTHEMIA ARE DRIVEN BY HYPOXIA-INDUCIBLE FACTORS (HIFS), INFLAMMATION, AND JAK2 V617F

EHA Library, Josef Prchal, 421607

THROMBIN POTENTIAL OF BLOOD MICROPARTICLES IN PATIENTS WITH PH-NEGATIVE MYELOPROLIFERATIVE NEOPLASMS

EHA Library, Natalia Silina, 421608

REAL-WORLD DATA DEMONSTRATED THE PROGNOSTIC IMPACT AND RUXOLITINIB DOSE OF MODERATE THROMBOCYTOPENIA IN MYELOFIBROSIS

EHA Library, Kazuya Shimoda, 421609

CONSENSUS ON THE DISEASE MANIFESTATIONS OF HYPEREOSINOPHILIC SYNDROME

EHA Library, Peter Vandenberghe, 421610

JAB-8263, A POTENT BET INHIBITOR, IN MYELOFIBROSIS AND OTHER ADVANCED MYELOID NEOPLASMS: RESULTS FROM A PHASE 1/2A STUDY

EHA Library, Bo Jiang, 421611

IMPACT OF PACRITINIB ON SYMPTOMS IN THROMBOCYTOPENIC MYELOFIBROSIS PATIENTS WHO REQUIRE RED BLOOD CELL TRANSFUSION

EHA Library, Stephen OH, 421612

ESTIMATED COST SAVINGS AND COMPLIANCE WITH TELEMEDICINE IN MYELOPROLIFERATIVE NEOPLASMS: A REAL-WORLD EXPERIENCE

EHA Library, Muhammad Ali Khan, 421613

CLINICAL AND DISEASE CHARACTERISTICS OF PATIENTS WITH MYELOFIBROSIS AND ESSENTIAL THROMBOCYTHEMIA WHO HARBOR A CALRETICULIN (CALR) GENE MUTATION: SUBANALYSIS OF THE MOST STUDY

EHA Library, Naveen Pemmaraju, 421614

EFFICACY AND SAFETY OF RUXOLITINIB IN CHINESE PATIENTS WITH POLYCYTHEMIA VERA RESISTANT/INTOLERANT TO HYDROXYUREA AND/OR INTERFERON-Α: INTERIM ANALYSIS OF A MULTICENTER, PROSPECTIVE, PHASE II STUDY

EHA Library, Zefeng Xu, 421615

ROP-ET: A PROSPECTIVE PHASE III TRIAL INVESTIGATING THE EFFICACY AND SAFETY OF ROPEGINTERFERON ALFA-2B IN ESSENTIAL THROMBOCYTHEMIA PATIENTS WITH LIMITED TREATMENT OPTIONS

EHA Library, Jean-Jacques Kiladjian, 421616

THROMBIN GENERATION IN MYELOPROLIFERATIVE NEOPLASMS

EHA Library, Natalia Silina, 421617

SEVEN-YEAR FOLLOW-UP OF PATIENTS WITH MYELOFIBROSIS TREATED WITH RUXOLITINIB: SINGLE CENTER EXPERIENCE

EHA Library, Stela Dimitrova, 421618

SENSITIVITY EVALUATION OF HETERODUPLEX ANALYSIS METHOD FOR SCREENING JAK2 EXON 12 MUTATIONS

EHA Library, Tatiana Subbotina, 421619

MEGAKARYOCYTE-DERIVED PF4/CXCL4 AND BCR::ABL1-NEGATIVE MYELOPROLIFERATIVE NEOPLASMS: A NEW POTENTIAL PROGNOSTIC FACTOR FOR DISEASE PROGRESSION?

EHA Library, Valentina Bellani, 421620

LONG-TERM SAFETY AND EFFICACY OF ROPEGINTERFERON ALFA-2B FOR PATIENTS WITH POLYCYTHEMIA VERA IN JAPAN

EHA Library, Keita Kirito, 421621

DIAGNOSTIC ACCURACY OF ERYTHROPOIETIN AND JAKPOT IN PREDICTING JAK2-POSITIVE ERYTHROCYTOSIS: A RETROSPECTIVE COHORT STUDY

EHA Library, Sabina Rajkumar, 421623

ROPEG-INTERFERON THERAPY IN POLYCYTHEMIA VERA: CLINICAL CONSIDERATION REGARDING EFFICACY AND SAFETY FROM A REAL-WORLD UNICENTRIC COHORT

EHA Library, Andrea Duminuco, 421624

RELATIONSHIP OF LYMPHOCYTE SUBSETS AND PROGNOSIS IN JUVENILE MYELOMONOCYTIC LEUKEMIA

EHA Library, Yunlong Chen, 421625

MOLECULAR AND HISTOPATHOLOGICAL CHARACTERISTICS OF MYELOPROLIFERATIVE NEOPLASMS ASSOCIATED WITH USUAL SITE THROMBOSIS.

EHA Library, Erika Morsia, 421626

DISEASE MANIFESTATIONS OF IDIOPATHIC HYPEREOSINOPHILIC SYNDROME: A SYSTEMATIC LITERATURE REVIEW

EHA Library, Priya Jain, 421628

IMPACT OF PROPHYLACTIC TREATMENT ON THIAMINE AND GASTROINTESTINAL ADVERSE EVENTS IN PATIENTS WITH MYELOFIBROSIS TREATED WITH FEDRATINIB IN THE FREEDOM2 TRIAL

EHA Library, Jean-Jacques Kiladjian, 421629

REAL-WORLD EXPERIENCE OF PEGYLATED INTERFERON ALFA-2B FOR MYELOPROLIFERATIVE NEOPLASMS

EHA Library, Qing Leng, 421630

ESTRADIOL AND HYPERCOAGULABILITY IN CALR-MUTANT PRIMARY MYELOFIBROSIS

EHA Library, Rossella Cacciola, 421631

JAKCALC: A MACHINE-LEARNING APPROACH TO RATIONALIZED JAK2 TESTING IN PATIENTS WITH ELEVATED HEMOGLOBIN LEVELS

EHA Library, Fatos KOSEOGLU, 421632

MONOCYTES SUBSETS DISTRIBUTION IN HISTIOCYTOSIS: KEY MARKER FOR DISEASE CHARACTERIZATION AND STAGING.

EHA Library, Sylvain Audia, 421633

ABSENCE OF THE ATM P.L2307F GERMLINE VARIANT IN 121 ITALIAN PEDIGREES WITH FAMILIAL MYELOPROLIFERATIVE NEOPLASMS

EHA Library, Oscar Borsani, 421634

THE PATTERNS AND ORGAN TREATMENT RESPONSE OF ERDHEIM-CHESTER DISEASE WITH CARDIAC INVOLVEMENT

EHA Library, Xin-xin Cao, 421635

PHASE 3 RANDOMIZED DOUBLE-BLIND STUDY EVALUATING SAFETY AND EFFICACY OF SELINEXOR, AN XPO1 INHIBITOR, PLUS RUXOLITINIB IN JAKI-NAÏVE MYELOFIBROSIS

EHA Library, Claire Harrison, 421636

A STUDY OF 50 PACIENTS WITH POLYCYTHEMIA INDUCED BY SODIUM-GLUCOSE COTRANSPORTER-2 INHIBITORS

EHA Library, Fernando Vázquez Lagos, 421637

ABSENCE OF QTC PROLONGATION WITH RUSFERTIDE, A HEPCIDIN MIMETIC FOR THE TREATMENT OF POLYCYTHEMIA VERA: A THOROUGH QT/QTC STUDY IN HEALTHY SUBJECTS

EHA Library, Nishit Modi, 421638

PLATELET PARAMETERS AND THEIR ROLE IN MYELOPROLIFERATIVE NEOPLASMS, THROMBOCYTOPENIA AND MYELODYSPLASTIC SYNDROME

EHA Library, Soon Hee Chang, 421639

PHASE 2 STUDY EVALUATING EFFICACY AND SAFETY OF SELINEXOR MONOTHERAPY IN PATIENTS WITH JAKI-NAÏVE MYELOFIBROSIS AND MODERATE THROMBOCYTOPENIA

EHA Library, Joseph M Scandura, 421640

AN OPEN-LABEL PHASE 3 STUDY OF BOMEDEMSTAT, A LYSINE-SPECIFIC DEMETHYLASE 1 (LSD1) INHIBITOR, FOR ESSENTIAL THROMBOCYTHEMIA

EHA Library, Ilya Kirgner, 421641

FIVE-YEAR NET SURVIVAL OF MYELOID NEOPLASMS: A POPULATION-BASED STUDY IN SPAIN (2002-2016)

EHA Library, rafael marcos-gragera, 421642

ASSESSING CLINICAL PREDICTORS OF ANEMIA IN MYELOFIBROSIS AND THE POTENTIAL ROLE FOR MOMELOTINIB AT A MULTI-ETHNIC INNER-CITY CENTER

EHA Library, Josette Kamel, 421643

FIRST EXPERIENCE WITH MOMELOTINIB IN A REAL-WORLD SETTING: A COHORT ANALYSIS FROM THE AGMT STUDY GROUP

EHA Library, Thomas Melchardt, 421644

JAK INHIBITORS FOR MYELOFIBROSIS: UNCOVERING CLINICAL GAPS IN PHYSICIAN KNOWLEDGE AND PRACTICE

EHA Library, Victoria Harvey-Jones, 421645

EXPLORING REAL-WORLD APPLICATIONS OF ROPEGINTERFERON IN POLYCYTHEMIA VERA

EHA Library, Novella Pugliese, 421646

CLINICAL FEATURES AND NEXT-GENERATION SEQUENCING LANDSCAPE OF POLYCYTHEMIA VERA AND IDIOPATHIC ERYTHROCYTOSIS: A CHINESE MONOCENTRIC RETROSPECTIVE STUDY

EHA Library, Jian Huang, 421647

EFFICACY AND SAFETY OF MIDOSTAURIN THERAPY IN PATIENTS WITH ADVANCED SYSTEMIC MASTOCYTOSIS: A SINGLE CENTER EXPERIENCE.

EHA Library, Agata Ogłoza, 421648

PRELIMINARY, SINGLE CENTER, REAL WORLD SAFETY AND EFFICACY DATA FROM THE TREATMENT OF MYELOFIBROSIS PATIENTS WITH MOMELOTINIB

EHA Library, Maria Dimou, 421649

ELEVATED VITAMIN B12 LEVELS IN MYELOPROLIFERATIVE NEOPLASMS: A COMPREHENSIVE ANALYSIS ON PREVALENCE, PROGNOSTIC SIGNIFICANCE AND TREATMENT RESPONSE

EHA Library, Shehab Fareed Abdelgabber, 421650

TIMING OF ALLO-HSCT IN CHRONIC MYELOMONOCYTIC LEUKEMIAS - A CHINESE REAL-WORLD STUDY

EHA Library, Jin Zhang, 421651

EFFICACY AND SAFETY OF MEPOLIZUMAB FOR THE TREATMENT OF PDGFRΑ-NEGATIVE HYPEREOSINOPHILIC SYNDROME: A SINGLE-CENTRE CONSECUTIVE CASE STUDY.

EHA Library, Carlota Portocarrero de las Heras Pérez, 421652

CONSENSUS-BASED BEST PRACTICE RECOMMENDATIONS FOR MF MANAGEMENT IN ROUTINE CLINICAL PRACTICE: SYSTEMATIC LITERATURE REVIEW AND CLINICAL PRACTICE RECOMMENDATIONS FROM AN ASIA-PACIFIC PERSPECTIVE

EHA Library, Harry Gill, 421653

ESSENTIAL THROMBOCYTHEMIA: CLINICAL CHARACTERISTICS, DIAGNOSTIC CHALLENGES AND THERAPEUTIC APPROACHES

EHA Library, cheybi ameni, 421654

IMPACT OF LABORATORY MARKERS AND CARDIOVASCULAR RISK FACTORS ON THROMBOSIS IN ESSENTIAL THROMBOCYTHEMIA

EHA Library, Marina Dokic, 421655

ANEMIA AND TRANSFUSION REQUIREMENT IN PATIENTS WITH MYELOFIBROSIS – A SINGLE CENTER EXPERIENCE

EHA Library, Ivanka Percic, 421656

AN OPEN-LABEL PHASE 2 STUDY OF BOMEDEMSTAT, A LYSINE-SPECIFIC DEMETHYLASE 1 (LSD1) INHIBITOR, FOR THE TREATMENT OF POLYCYTHEMIA VERA

EHA Library, Lindsay Rein, 421657

SUMMIT PART 2 TRIAL IN PROGRESS: A GLOBAL, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, 3-PART PHASE 2 CLINICAL TRIAL OF BEZUCLASTINIB IN ADULT PATIENTS WITH NONADVANCED SYSTEMIC MASTOCYTOSIS

EHA Library, Andreas Reiter, 421658

ASSISTED REPRODUCTIVE TECHNOLOGY IN PATIENTS WITH ESSENTIAL THROMBOCYTHEMIA:  A NEW CLINICAL CHALLENGE

EHA Library, Cristina Bucelli, 421659

SKIN INVOLVEMENT PREDICTS SYMPTOMATIC BURDEN IN INDOLENT SYSTEMIC MASTOCYTOSIS - REPORT FROM A NATIONAL SURVEY IN PORTUGAL

EHA Library, Christopher J. Saunders, 421660

EFFICACY AND SAFETY OF PEGYLATED INTERFERON ALFHA-2B THERAPY IN POLYCYTHEMIA VERA AND ESSENTIAL THROMBOCYTHEMIA IN THE REAL WORLD

EHA Library, Yueyue Zheng, 421661

RUXOLITINIB IN PATIENTS WITH POLYCYTHAEMIA VERA: FINDINGS FROM A MANAGED ACCESS PROGRAM

EHA Library, Thirupathi Pattipaka, 421662

PREDICTIVE FACTORS FOR THE EFFECTIVENESS OF TARGET THERAPY FOR MYELOFIBROSIS

EHA Library, Olga Vinogradova, 421663

REAL-WORLD EFFICACY AND SAFETY OF RUXOLITINIB IN THE TREATMENT OF ELDERLY MYELOFIBROSIS PATIENTS: A RETROSPECTIVE STUDY

EHA Library, Xiaohan Liu, 421664

HOVON 172: TASQFORCE; A PHASE 1B/2 TRIAL WITH TASQUINIMOD IN PATIENTS WITH MYELOFIBROSIS (PRIMARY, POST-PV OR POST-ET) REFRACTORY TO OR INTOLERANT FOR JAK2 INHIBITION

EHA Library, Peter te Boekhorst, 421665

RUXOLITINIB-AZACITIDINE COMBINATION THERAPY FOR ACCELERATED-PHASE MYELOPROLIFERATIVE NEOPLASMS

EHA Library, Fatma Keklik Karadag, 421666

PROMISE: INVESTIGATION INTO THE COMBINATION OF PLX2853 WITH RUXOLITINIB IN PATIENTS WITH INTERMEDIATE-2 OR HIGH RISK MYELOFIBROSIS NOT RECEIVING AN ADEQUATE RESPONSE WITH RUXOLITINIB ALONE

EHA Library, Adam Mead, 421667

RETROSPECTIVE ANALYSIS OF RUXOLITINIB TREATMENT IN MYELOPROLIFERATIVE DISORDERS

EHA Library, Guillermo Haces Tirado, 421668

CAROTID INTIMAL THICKNESS SCREENING IN MYELOPROLIFERATIVE NEOPLASM PATIENTS AGED YOUNGER THAN 60 YEARS

EHA Library, Sara El-sayed, 421669

RESULTS OF TARGETED THERAPY OF ADVANCED SYSTEMIC MASTOCYTOSIS IN REAL CLINICAL PRACTICE: SINGLE CENTER EXPERIENCE

EHA Library, Dzhariiat Shikhbabaeva, 421670

APEX PART 2 TRIAL IN PROGRESS: A RANDOMIZED, PHASE 2 OPEN-LABEL CLINICAL STUDY OF BEZUCLASTINIB IN ADULT PATIENTS WITH ADVANCED SYSTEMIC MASTOCYTOSIS

EHA Library, Khalid Shoumariyeh, 421671

CLASSIC HODGKIN LYMPHOMA IN CHILDREN AT THE TUNISIAN CENTER

EHA Library, amira guizeni, 421672

QUANTITATIVE PET PARAMETERS ON BASELINE AND INTERIM FDG-PET SCANS IN HODGKIN LYMPHOMA AS A PROGNOSTIC MARKER

EHA Library, Sze Ting Lee, 421673

EXPRESSION PATTERNS OF GATA3 IN CLASSICAL HODGKIN LYMPHOMA. A CLINICO- PATHOLOGICAL STUDY

EHA Library, Andreas Epameinondas Koumpis, 421674

CLINICAL CHARACTERISTICS AND OUTCOME ASSOCIATED WITH THE EXPRESSION OF NEUTROPHIL EXTRACELLULAR TRAPS MARKERS IN NEWLY DIAGNOSED CLASSIC HODGKIN LYMPHOMA.

EHA Library, Chantiya Chanswangphuwana, 421675

THERAPEUTIC RESULTS OF A TUNISIAN PROSPECTIVE NON-RANDOMIZED ADULT HODGKIN LYMPHOMA STUDY: A SINGLE-INSTITUTION EXPERIENCE ABOUT 114 ADULT PATIENTS.

EHA Library, Khouloud Mezghani, 421676

EVALUATING EFFICACY OF NON-DOXORUBICIN AND DOXORUBICIN-BASED CHEMOTHERAPY REGIMENS IN SEVERELY G6PD DEFICIENT HODGKIN LYMPHOMA PATIENTS IN BAHRAIN

EHA Library, Fatima Sabri, 421677

EFFECT OF ONLINE EDUCATION ACTIVITY ON HEMATOLOGIST/ONCOLOGISTS’ ABILITY TO TREAT PATIENTS WITH IMMUNOTHERAPY FOR RELAPSED/REFRACTORY CLASSICAL HODGKIN LYMPHOMA

EHA Library, Victoria Harvey-Jones, 421678

SINGLE-CENTER EXPERIENCE OF NIVOLUMAB USE FOR REFRACTORY/RELAPSED LYMPHOMA PATIENTS IN LIMITED RESOURCES AREA

EHA Library, Lusine Harutyunyan, 421679

THE ROLE OF 18FDG PET-CT IN THE INITIAL STAGING OF HODGKIN'S LYMPHOMA: INSIGHTS FROM MONASTIR, TUNISIA

EHA Library, Kmar Mrad, 421680

PRELIMINARY RESULTS OF THE PHASE 2 STUDY EVALUATING THE SAFETY AND EFFICACY OF PEMBROLIZUMAB (KEYTRUDA) WITH BENDAMUSTINE (TREANDA) IN RELAPSED/REFRACTORY HODGKIN LYMPHOMA (KESTREL-01)

EHA Library, Chathuri Abeyakoon, 421681

WITH NEW DRUGS COMES NEW COMPLICATIONS: NIVOLUMAB INDUCED ACQUIRED HEMOPHILIA A AND HLH IN HODGKIN LYMPHOMA SUCCESSFULLY TREATED WITH RITUXIMAB AND STEROIDS

EHA Library, Sachin Bansal, 421682

MOBILIZATION AND HARVEST OF STEM CELLS AFTER SALVAGE THERAPY WITH BRENTUXIMAB VEDOTIN FOR RELAPSED/REFRACTORY HODGKIN'S LYMPHOMA

EHA Library, Anatoly Uss, 421683